PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
43.645
+0.135 (+0.31%)
As of 9:43AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close43.510
Open43.000
Bid43.350 x 1000
Ask43.440 x 800
Day's Range43.400 - 43.680
52 Week Range33.200 - 43.680
Volume1,163,560
Avg. Volume19,596,235
Market Cap255.852B
Beta0.87
PE Ratio (TTM)11.66
EPS (TTM)3.744
Earnings DateOct 30, 2018
Forward Dividend & Yield1.36 (3.17%)
Ex-Dividend Date2018-08-02
1y Target Est42.37
Trade prices are not sourced from all markets
  • ACCESSWIRE2 hours ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Pfizer

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist2 hours ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • MarketWatch19 hours ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • Business Wire19 hours ago

    New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting

    —Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meetin

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist23 hours ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Watson Health Still the Key Driver for IBM’s AI Business
    Market Realistyesterday

    Watson Health Still the Key Driver for IBM’s AI Business

    The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.

  • Business Wireyesterday

    Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realistyesterday

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
    Zacksyesterday

    Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

    Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacksyesterday

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realistyesterday

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realistyesterday

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • InvestorPlaceyesterday

    Cronos Gets Bigger As It Partners With Ginkgo Bioworks

    From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.

  • Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
    Zacks2 days ago

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realist2 days ago

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist2 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realist2 days ago

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • This cancer-fighting biotech sped from startup to IPO filing in 10 months
    American City Business Journals2 days ago

    This cancer-fighting biotech sped from startup to IPO filing in 10 months

    The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.

  • Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
    Market Realist2 days ago

    Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond

    On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.

  • Business Wire4 days ago

    Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress

    Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with profound psychological consequences. Both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 (33.6 points and 49.5 points for JAK3 and TYK2/JAK1, respectively) as measured by the Severity of Alopecia Tool (SALT) score (100 point scale).

  • Wall Street Analysts Are Mostly Positive on Merck in September
    Market Realist5 days ago

    Wall Street Analysts Are Mostly Positive on Merck in September

    Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.

  • Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
    Zacks5 days ago

    Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

    Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.

  • How Spark Therapeutics Is Positioned in 2018
    Market Realist5 days ago

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks5 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Pharma/Biotech Stocks to Watch This Prostate Cancer Month
    Zacks5 days ago

    Pharma/Biotech Stocks to Watch This Prostate Cancer Month

    Here we highlight a few companies that are focused on developing treatments for prostate cancer.